News

MPR1d
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring
The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.
Medscape11d
Continuous Glucose Monitoring: For Insulin Users and Beyond
Discussions at the Advanced Technologies & Treatments for Diabetes meeting covered CGM use in non–insulin-treated people with ...
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...
Drug Delivery Business1d
Dexcom wins FDA nod for 15-day CGM
Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.
2 Minute Medicine3d
Automated insulin delivery improves glycemic control over continuous glucose monitoring
Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater ...
Morningstar9d
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Unlike traditional continuous glucose monitors that measure glucose levels ... Philip Morris and AT&T rank among the best stocks in Q1 2025, while the worst include Trade Desk and Deckers Brands.
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...